Calithera Biosciences (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced two new clinical trial collaborations to evaluate Pfizer’s palbociclib, also known as IBRANCE, and the investigational dual-mechanism poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib, each in combination with Calithera’s glutaminase inhibitor CB-839. As part of the collaboration, Pfizer … Continued